# Nuclide record prostate-nmcrpc (indication). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/indications/prostate-nmcrpc/>
  a schema:MedicalCondition ;
  nuclide:kind "indication" ;
  schema:identifier "prostate-nmcrpc" ;
  schema:name "Non-metastatic castration-resistant prostate cancer"@en ;
  schema:alternateName "nmCRPC"@en, "M0 CRPC"@en, "Non-metastatic CRPC"@en, "Rising PSA on hormone therapy without metastases"@en ;
  schema:description "Non-metastatic castration-resistant prostate cancer is a PSA that keeps rising on hormone therapy while scans still show nothing. Three androgen receptor blockers, apalutamide, enzalutamide and darolutamide, each delay metastasis by about two years and lengthen life, and darolutamide is the gentlest."@en ;
  schema:url <https://nuclide.cc/indications/prostate-nmcrpc/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Castration-resistant_prostate_cancer> ;
  schema:citation <https://en.wikipedia.org/wiki/Castration-resistant_prostate_cancer>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1459> ;
  nuclide:tag "subtype-page" ;
  nuclide:related <https://nuclide.cc/indications/prostate-bcr/>, <https://nuclide.cc/indications/prostate-mhspc/>, <https://nuclide.cc/indications/prostate-mcrpc/> ;
  nuclide:terms <https://nuclide.cc/terms/psa-kinetics/> ;
  nuclide:trials <https://nuclide.cc/trials/prosper/> ;
  nuclide:pipeline <https://nuclide.cc/technologies/psma-pet/> ;
  nuclide:standardOfCare <https://nuclide.cc/drugs/enzalutamide/>, <https://nuclide.cc/technologies/psma-pet/>, <https://nuclide.cc/terms/mcrpc-mhspc/> .